Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Sponsor
National Health Research Institutes, Taiwan
Study ID
NCT07151326
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    All patients will be treated with cabozantinib at 60 mg once daily.

Study Details

1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment. 2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.

Key Dates

Start date
Sep 30, 2025
Status verified
Aug 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib
    All patients will be treated with cabozantinib at 60 mg once daily.

Primary Outcome Measure

Progression-free rate at 6 months [ Time Frame: 30 months ]

Central Contacts

Related Studies